Knight Takes its Dose of Medison
(firmenpresse) - MONTREAL, CANADA -- (Marketwired) -- 09/09/15 -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading Canadian specialty pharmaceutical company, announced today its previously announced transaction with Medison Biotech (1995) Ltd. ("Medison"), Israel's leading independent specialty pharmaceutical company, has closed.
To solidify the strategic collaboration between the companies, Knight has acquired a 28.3% equity interest in Medison valued at $80 million (US$60 million) in exchange for approximately a 10% equity interest in Knight (10.33 million common shares of Knight held by Medison and its controlling shareholder). Up to an additional 660,000 Knight shares may be issued if Medison meets certain financial targets over the next two years.
About Medison
Backed by three generations of experience in the healthcare industry since 1937, Medison is Israel's leading specialty pharmaceutical and therapeutic device company. Medison is focused on delivering innovative healthcare solutions to the Israeli and Romanian markets, including but not limited to early access programs, government registration and reimbursement, medical affairs, marketing and logistics. Medison is the exclusive Israeli partner for leading global pharma companies such as Amgen®, Biogen®, Shire® and Ipsen®. Medison also operates a fully owned subsidiary in Romania based on replicating its success in Israel, and currently represents Biogen®. For more information, please visit .
About Knight Therapeutics Inc.
Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian and select international markets. Knight's shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the Company's web site at or .
Forward-Looking Statement
This document contains forward-looking statements for Knight and its subsidiaries. These forward looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight and its subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations are discussed in Knight's Annual Report and in Knight's Annual Information Form for the year ended December 31, 2014. Knight disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events, except as required by law.
Contacts:
Knight Therapeutics Inc.
Jeffrey Kadanoff, P.Eng., MBA
Chief Financial Officer
514-484-GUD1 (4831)
514-481-4116 (FAX) (FAX)
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 09.09.2015 - 12:00 Uhr
Sprache: Deutsch
News-ID 418786
Anzahl Zeichen: 0
contact information:
Town:
MONTREAL, CANADA
Kategorie:
Drugs
Diese Pressemitteilung wurde bisher 217 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Knight Takes its Dose of Medison"
steht unter der journalistisch-redaktionellen Verantwortung von
Knight Therapeutics Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
